甲状腺癌是女性第7位常见的恶性肿瘤，乳头状甲状腺癌占其中的90%以上。近期研究发现，在甲状腺结节患者中，血清促甲状腺激素（TSH）升高是乳头状甲状腺癌的危险因素，但TSH-cAMP通路如何诱导甲状腺滤泡细胞恶变的分子机制并不清楚。我们前期的研究发现，受TSH调控的FOXE1基因是乳头状甲状腺癌易感基因，而FOXE1是调控甲状腺滤泡细胞分化、增殖的潜在的关键因子。我们将进一步分析FOXE1基因的遗传变异在接受TSH刺激，从而导致其调控甲状腺滤泡细胞分化、增殖等功能中的重要作用；同时研究FOXE1在不同分化阶段的甲状腺滤泡细胞中的动态表达情况及其对于甲状腺滤泡细胞、甲状腺肿瘤细胞生物学行为的影响，并深入研究FOXE1在甲状腺滤泡细胞及肿瘤细胞中对下游基因的调控，最终揭示TSH-cAMP-FOXE1通路在TSH诱发乳头状甲状腺癌过程中的分子机制，为临床乳头状甲状腺癌的诊断和治疗提供理论依据。

Thyoid cancer is the most popular endocrine malignant, which is the 7th cancer in women, and about 90% thyoid cancer is papillary thyroid cancer. Recently reasearches show high level thyroid stimulating hormone（TSH） causes higher risk of thyroid cancer. In our research, we confirm this phenomenon in Chinese patients. Unfortunately, the molecular mechanism of how TSH-cAMP pathway casused thyroid cancer was unclear,we find FOXE1 gene: rs1867277（A>G）,rs907577（C>T）and rs3758248(C>T) are the suspective SNP of papillary thyroid cancer. TSH could cause the risk higher in these patients. In future study, we will analysis the genetic variant of FOXE1 under the stimulation of TSH, and furthermore we will investigate the differentiation and proliferation of thyroid follicle cell under TSH stiumlation. Meanwhile, this study will focuse on the dynamic genetic change of TSH-cAMP-FOXE1 pathway in the papillary thyroid cancer and benign thyroid neoplasm. Finally，our research will elucidate the mechanism of TSH-cAMP-FOXE1 pathway in the papillary thyroid cancer and provide the expanlation for the clinical diagnose and treatment of papillary thyroid cancer.